Posted by Michael Wonder on 04 Jul 2024
Full-Life Technologies granted FDA fast track designation for 225Ac-FL-020 for the treatment of metastatic castration resistant prostate cancer
2 July 2024 - Full-Life Technologies today announced that the US FDA has granted fast track designation for 225Ac-FL-020, the company's lead radiopharmaceutical, which targets prostate-specific membrane antigen, for the treatment of metastatic castration resistant prostate cancer.
225Ac-FL-020 is a novel, potential best in class, next generation PSMA targeting radionuclide drug conjugate (RDC) that entered global Phase I clinical studies in 2024.
